Nanomedicine News RSS Feed - Nanomedicine

Iron Oxide Nanoparticles Selectively Target Tumor Cells

Iron Oxide Nanoparticles Selectively Target Tumor Cells

Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells. [More]
Magnetic Nanoparticles Open the Blood-Brain Barrier to Deliver Molecules to the Brain

Magnetic Nanoparticles Open the Blood-Brain Barrier to Deliver Molecules to the Brain

Magnetic nanoparticles can open the blood-brain barrier and deliver molecules directly to the brain, say researchers from the University of Montreal, Polytechnique Montréal, and CHU Sainte-Justine. [More]
Two Drugs Within Specially Designed Mesoporous Silica Nanoparticle Can Shrink Human Pancreas Tumors

Two Drugs Within Specially Designed Mesoporous Silica Nanoparticle Can Shrink Human Pancreas Tumors

Scientists at UCLA’s California NanoSystems Institute and Jonsson Comprehensive Cancer Center have combined their nanotechnology expertise to create a new treatment that may solve some of the problems of using chemotherapy to treat pancreatic cancer. [More]
Global Nanotechnology in Medical Devices Market Forecast to Reach $8.5 Billion by 2019

Global Nanotechnology in Medical Devices Market Forecast to Reach $8.5 Billion by 2019

Global Nanotechnology in Medical Devices Market is was valued at around $5 Billion in 2014 and expected to reach around $8.5 Billion by 2019 with a CAGR of around 11-12% during the forecast period 2014 - 2019 - Says a New Research Available at RnRMarketResearch.com [More]
MagForce Announces Installation of NanoActivator at Cologne University Hospital

MagForce Announces Installation of NanoActivator at Cologne University Hospital

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, today announced the installation of the fourth NanoActivator(R). [More]
Cerulean Reports Top-Line Results from CRLX101-Avastin Combination Phase 1b/2 Trial for Relapsed Renal Cell Carcinoma

Cerulean Reports Top-Line Results from CRLX101-Avastin Combination Phase 1b/2 Trial for Relapsed Renal Cell Carcinoma

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that a Phase 1b/2 trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin® in relapsed renal cell carcinoma (RCC) achieved its primary endpoint of at least 50% of patients achieving four months of progression free survival (PFS). [More]
Nanotechnology and Transdermal Drug Delivery to Treat Acne

Nanotechnology and Transdermal Drug Delivery to Treat Acne

Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples. [More]
Coating Scaffold with Self-Assembling Nanofibers Decreases Inflammation

Coating Scaffold with Self-Assembling Nanofibers Decreases Inflammation

A new technique to create tissue-engineered bladders has been shown to decrease scarring and significantly increase tissue growth. The bladders are produced using scaffolds coated with anti-inflammatory peptides. [More]
AACR Annual Meeting: Three Abstracts on BIND Therapeutics’s Accurins to be Presented

AACR Annual Meeting: Three Abstracts on BIND Therapeutics’s Accurins to be Presented

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia. [More]
LamdaGen Opens Wholly-Owned Subsidiary, LamdaGen Nanotechnology Taiwan

LamdaGen Opens Wholly-Owned Subsidiary, LamdaGen Nanotechnology Taiwan

LamdaGen Corporation, a nano-technology platform company that provides LSPR based plasmonic sensors and systems for In Vitro Diagnostics (IVD), announced the opening of a wholly-owned subsidiary, LamdaGen Nanotechnology Taiwan Co., LTD. (LamdaGen Taiwan). [More]